Precision medicine engaging nucleoside analogues: New advances to a conventional arsenal

被引:0
作者
Yehia, Heba [1 ]
机构
[1] Natl Res Ctr, Pharmaceut & Drug Ind Res Inst, Dept Chem Nat & Microbial Prod, Cairo 12622, Egypt
关键词
Precision medicine; Personalized medicine; Patient idiosyncrasy; Biomarkers; Nucleoside analogues; POLYMORPHISMS; CANCER; PREDICTORS; DISEASE; FUTURE; CDA;
D O I
10.1007/s13596-024-00747-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Precision medicine (PM) is increasingly being described as a paradigm shift in our understanding of medicine and as the future of clinical practice since it promises the possibility to individualize the healthcare in order to achieve optimal treatment with minimal adversity. Advances in the fields of omics, next generation sequencing (NGS), artificial intelligence (AI) and big data have strongly augmented this approach and rendered it clinically feasible instead of relying on the conventional nosology and broad symptomatic presentations. Oncology has, so far, benefited the most from this strategy as evidenced by genetic markers and biomarkers-guided pharmacotherapeutics that have found their way into guidelines and protocols. Meanwhile, nucleoside analogues, that represent a fundamental class in solid and hematologic tumors treatment, are still far from being adequately included in this trending modality due to lacking sufficient valid clinical proofs. The well-studied drugs' paths, however, pave the way towards this goal, hoping to transfer the hype into bedside reality.
引用
收藏
页码:27 / 37
页数:11
相关论文
共 64 条
[1]   Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients [J].
Abbaspour, Alireza ;
Dehghani, Mehdi ;
Setayesh, Mahtab ;
Tavakkoli, Marjan ;
Rostamipour, Hossein Ali ;
Ghorbani, Marziyeh ;
Ramzi, Mani ;
Omidvari, Shapour ;
Moosavi, Fatemeh ;
Firuzi, Omidreza .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 92 (06) :475-483
[2]  
Aldeen Majeed Ali Amal, 2023, Asian Pac J Cancer Prev, V24, P4219, DOI 10.31557/APJCP.2023.24.12.4219
[3]  
Aramini B, 2020, LUNG CANC
[4]   Use Your Words Carefully: What is a Chronic Disease? [J].
Bernell, Stephanie ;
Howard, Steven W. .
FRONTIERS IN PUBLIC HEALTH, 2016, 4
[5]   Optimizing Precision Medicine for Public Health [J].
Bilkey, Gemma A. ;
Burns, Belinda L. ;
Coles, Emily P. ;
Mahede, Trinity ;
Baynam, Gareth ;
Nowak, Kristen J. .
FRONTIERS IN PUBLIC HEALTH, 2019, 7
[6]   Precision Medicine Versus Evidence-Based Medicine Individual Treatment Effect Versus Average Treatment Effect [J].
Blackstone, Eugene H. .
CIRCULATION, 2019, 140 (15) :1236-1238
[7]   How to Integrate Personalized Medicine into Prevention? Recommendations from the Personalized Prevention of Chronic Diseases (PRECeDI) Consortium [J].
Boccia, Stefania ;
Pastorino, Roberta ;
Ricciardi, Walter ;
Adany, Roza ;
Barnhoorn, Floris ;
Boffetta, Paolo ;
Cornel, Martina C. ;
De Vito, Corrado ;
Gray, Muir ;
Jani, Anant ;
Lang, Michael ;
Roldan, Jim ;
Rosso, Annalisa ;
Sanchez, Jose Manuel ;
Van Dujin, Cornelia M. ;
Van El, Carla G. ;
Villari, Paolo ;
Zawati, Ma'n H. .
PUBLIC HEALTH GENOMICS, 2020, 22 (5-6) :208-214
[8]   Precision medicine in asthma: linking phenotypes to targeted treatments [J].
Chung, Kian Fan .
CURRENT OPINION IN PULMONARY MEDICINE, 2018, 24 (01) :4-10
[9]   Nucleoside analogs: ready to enter the era of precision medicine? [J].
Ciccolini, Joseph ;
Serdjebi, Cindy ;
Hau Le Thi Thu ;
Lacarelle, Bruno ;
Milano, Gerard ;
Fanciullino, Raphaelle .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (08) :865-877
[10]   Multiplexed therapeutic drug monitoring (TDM) of antiviral drugs by LC-MS/MS [J].
Conti, M. ;
Cavedagna, T. Matulli ;
Ramazzotti, E. ;
Mancini, R. ;
Calza, L. ;
Rinaldi, M. ;
Badia, L. ;
Guardigni, V ;
Viale, P. ;
Verucchi, G. .
CLINICAL MASS SPECTROMETRY, 2018, 7 :6-17